Artivion (NYSE:AORT) Stock Price Down 5.5% – Here’s What Happened

Artivion, Inc. (NYSE:AORT) was down 5.5% on Tuesday . The company traded as low as $35.35 and last traded at $35.3210. Approximately 266,449 shares were traded during trading, a decline of 32% from the average daily volume of 389,271 shares. The stock had previously closed at $37.39.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday. Citizens Jmp increased their price objective on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Needham & Company LLC reissued a “buy” rating and set a $58.00 price objective on shares of Artivion in a research note on Monday, February 2nd. Finally, Canaccord Genuity Group decreased their price objective on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.97.

Artivion Trading Down 5.2%

The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $1.70 billion, a PE ratio of 176.20 and a beta of 1.59. The company’s 50-day simple moving average is $42.72 and its 200 day simple moving average is $43.18.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.14 by $0.03. The business had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The firm’s revenue for the quarter was up 19.2% compared to the same quarter last year. As a group, sell-side analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Insider Activity at Artivion

In related news, SVP Jean F. Holloway sold 7,315 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $45.30, for a total transaction of $331,369.50. Following the sale, the senior vice president directly owned 156,093 shares of the company’s stock, valued at $7,071,012.90. This represents a 4.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Amy Horton sold 4,572 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $44.42, for a total value of $203,088.24. Following the transaction, the chief accounting officer directly owned 130,058 shares of the company’s stock, valued at approximately $5,777,176.36. This represents a 3.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 42,808 shares of company stock worth $1,943,219. Corporate insiders own 8.10% of the company’s stock.

Institutional Trading of Artivion

Institutional investors have recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd increased its holdings in Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after acquiring an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Artivion during the third quarter worth $27,000. Larson Financial Group LLC boosted its holdings in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after acquiring an additional 563 shares during the period. USA Financial Formulas grew its stake in shares of Artivion by 163.5% in the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after purchasing an additional 703 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after buying an additional 538 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.